DFTXDefinium Therapeutics, Inc.
$36.91+308% 1Y
$36.91
$9.5452 weeks$47.08
DFTX in its own filings
DFTX's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
157
Events found in the filings · across 503 filings · the record starts in 2021
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 14, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 23, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountanthistorical
- 2022-03-28
- Delisting notice / listing-rule failurehistorical
- 2022-06-02
- SEC comment-letter activity7 occurrences
- 2024-04-26
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 14, 2026On September 14, 2026, the Company posted a presentation discussing the Panorama topline data (the “Presentation”) to its website.Regulation FD disclosure · Form 8-K
- Sep 8, 2026On September 8, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that the U.S. Food and Drug Administration has granted breakthrough designation to the Company’s DT120 ODT program for the treatment of major depressive disorder.Other event · Form 8-K
- Aug 12, 2026The information furnished pursuant to this.Regulation FD disclosure · Form 8-K
- Jun 24, 2026On June 23, 2026, Definium Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, and BofA Securities, Inc., as representatives of the several underwriters named therein (the “Underwriters”), in …Material agreement entered · Form 8-K
- Jun 22, 2026On June 22, 2026, the Company posted a presentation discussing the Emerge topline data (the “Presentation”) on its website.Regulation FD disclosure · Form 8-K
- Jun 12, 20262025 Equity Incentive Plan As described in.Director or officer change · Form 8-K
- May 19, 2026On May 19, 2026, Definium Therapeutics, Inc. posted an updated corporate presentation on its website.Other event · Form 8-K
- May 12, 2026On May 12, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release announcing the first patient dosed in the Company's Phase 3 Ascend study of DT120 Orally Disintegrating Tablet in Major Depressive Disorder.Other event · Form 8-K
- Apr 22, 2026On April 22, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing clinical and commercial updates presented at the Company's Investor and Analyst Day.Other event · Form 8-K
- Feb 26, 2026Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…